484 related articles for article (PubMed ID: 24362439)
1. Selective CDK9 inhibition overcomes TRAIL resistance by concomitant suppression of cFlip and Mcl-1.
Lemke J; von Karstedt S; Abd El Hay M; Conti A; Arce F; Montinaro A; Papenfuss K; El-Bahrawy MA; Walczak H
Cell Death Differ; 2014 Mar; 21(3):491-502. PubMed ID: 24362439
[TBL] [Abstract][Full Text] [Related]
2. EV-T synergizes with AZD5582 to overcome TRAIL resistance through concomitant suppression of cFLIP, MCL-1, and IAPs in hepatocarcinoma.
Su K; Yuan Q; Hou H; Ke C; Huang C; Li S; Sun J; Yuan X; Lin Y; Chen Y; Xin H; Liang X; Du Z; Yuan Z
J Mol Med (Berl); 2022 Apr; 100(4):629-643. PubMed ID: 35247069
[TBL] [Abstract][Full Text] [Related]
3. Roscovitine sensitizes breast cancer cells to TRAIL-induced apoptosis through a pleiotropic mechanism.
Ortiz-Ferrón G; Yerbes R; Eramo A; López-Pérez AI; De Maria R; López-Rivas A
Cell Res; 2008 Jun; 18(6):664-76. PubMed ID: 18458681
[TBL] [Abstract][Full Text] [Related]
4. Antipsychotic agent thioridazine sensitizes renal carcinoma Caki cells to TRAIL-induced apoptosis through reactive oxygen species-mediated inhibition of Akt signaling and downregulation of Mcl-1 and c-FLIP(L).
Min KJ; Seo BR; Bae YC; Yoo YH; Kwon TK
Cell Death Dis; 2014 Feb; 5(2):e1063. PubMed ID: 24556678
[TBL] [Abstract][Full Text] [Related]
5. Rocaglamide overcomes tumor necrosis factor-related apoptosis-inducing ligand resistance in hepatocellular carcinoma cells by attenuating the inhibition of caspase-8 through cellular FLICE-like-inhibitory protein downregulation.
Luan Z; He Y; He F; Chen Z
Mol Med Rep; 2015 Jan; 11(1):203-11. PubMed ID: 25333816
[TBL] [Abstract][Full Text] [Related]
6. The multikinase inhibitor sorafenib potentiates TRAIL lethality in human leukemia cells in association with Mcl-1 and cFLIPL down-regulation.
Rosato RR; Almenara JA; Coe S; Grant S
Cancer Res; 2007 Oct; 67(19):9490-500. PubMed ID: 17909059
[TBL] [Abstract][Full Text] [Related]
7. Down-regulation of cFLIP following reovirus infection sensitizes human ovarian cancer cells to TRAIL-induced apoptosis.
Clarke P; Tyler KL
Apoptosis; 2007 Jan; 12(1):211-23. PubMed ID: 17136319
[TBL] [Abstract][Full Text] [Related]
8. Galangin sensitizes TRAIL-induced apoptosis through down-regulation of anti-apoptotic proteins in renal carcinoma Caki cells.
Han MA; Lee DH; Woo SM; Seo BR; Min KJ; Kim S; Park JW; Kim SH; Choi YH; Kwon TK
Sci Rep; 2016 Jan; 6():18642. PubMed ID: 26725939
[TBL] [Abstract][Full Text] [Related]
9. Targeting acute myeloid leukemia by dual inhibition of PI3K signaling and Cdk9-mediated Mcl-1 transcription.
Thomas D; Powell JA; Vergez F; Segal DH; Nguyen NY; Baker A; Teh TC; Barry EF; Sarry JE; Lee EM; Nero TL; Jabbour AM; Pomilio G; Green BD; Manenti S; Glaser SP; Parker MW; Lopez AF; Ekert PG; Lock RB; Huang DC; Nilsson SK; Récher C; Wei AH; Guthridge MA
Blood; 2013 Aug; 122(5):738-48. PubMed ID: 23775716
[TBL] [Abstract][Full Text] [Related]
10. Suppression of cFLIP by lupeol, a dietary triterpene, is sufficient to overcome resistance to TRAIL-mediated apoptosis in chemoresistant human pancreatic cancer cells.
Murtaza I; Saleem M; Adhami VM; Hafeez BB; Mukhtar H
Cancer Res; 2009 Feb; 69(3):1156-65. PubMed ID: 19176377
[TBL] [Abstract][Full Text] [Related]
11. Akt-mediated eminent expression of c-FLIP and Mcl-1 confers acquired resistance to TRAIL-induced cytotoxicity to lung cancer cells.
Wang X; Chen W; Zeng W; Bai L; Tesfaigzi Y; Belinsky SA; Lin Y
Mol Cancer Ther; 2008 May; 7(5):1156-63. PubMed ID: 18483303
[TBL] [Abstract][Full Text] [Related]
12. AMPK-independent down-regulation of cFLIP and sensitization to TRAIL-induced apoptosis by AMPK activators.
García-García C; Fumarola C; Navaratnam N; Carling D; López-Rivas A
Biochem Pharmacol; 2010 Mar; 79(6):853-63. PubMed ID: 19896469
[TBL] [Abstract][Full Text] [Related]
13. Human embryonic and induced pluripotent stem cells express TRAIL receptors and can be sensitized to TRAIL-induced apoptosis.
Vinarsky V; Krivanek J; Rankel L; Nahacka Z; Barta T; Jaros J; Andera L; Hampl A
Stem Cells Dev; 2013 Nov; 22(22):2964-74. PubMed ID: 23806100
[TBL] [Abstract][Full Text] [Related]
14. Mcl-1 mediates tumor necrosis factor-related apoptosis-inducing ligand resistance in human cholangiocarcinoma cells.
Taniai M; Grambihler A; Higuchi H; Werneburg N; Bronk SF; Farrugia DJ; Kaufmann SH; Gores GJ
Cancer Res; 2004 May; 64(10):3517-24. PubMed ID: 15150106
[TBL] [Abstract][Full Text] [Related]
15. The eIF4E/eIF4G interaction inhibitor 4EGI-1 augments TRAIL-mediated apoptosis through c-FLIP Down-regulation and DR5 induction independent of inhibition of cap-dependent protein translation.
Fan S; Li Y; Yue P; Khuri FR; Sun SY
Neoplasia; 2010 Apr; 12(4):346-56. PubMed ID: 20360945
[TBL] [Abstract][Full Text] [Related]
16. Evodiamine induces apoptosis and enhances TRAIL-induced apoptosis in human bladder cancer cells through mTOR/S6K1-mediated downregulation of Mcl-1.
Zhang T; Qu S; Shi Q; He D; Jin X
Int J Mol Sci; 2014 Feb; 15(2):3154-71. PubMed ID: 24566141
[TBL] [Abstract][Full Text] [Related]
17. Wogonin enhances antitumor activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo through ROS-mediated downregulation of cFLIPL and IAP proteins.
Yang L; Wang Q; Li D; Zhou Y; Zheng X; Sun H; Yan J; Zhang L; Lin Y; Wang X
Apoptosis; 2013 May; 18(5):618-26. PubMed ID: 23371323
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of BET bromodomain-dependent XIAP and FLIP expression sensitizes KRAS-mutated NSCLC to pro-apoptotic agents.
Klingbeil O; Lesche R; Gelato KA; Haendler B; Lejeune P
Cell Death Dis; 2016 Sep; 7(9):e2365. PubMed ID: 27607580
[TBL] [Abstract][Full Text] [Related]
19. CRISPR-mediated upregulation of DR5 and downregulation of cFLIP synergistically sensitize HeLa cells to TRAIL-mediated apoptosis.
Poondla N; Chandrasekaran AP; Heese K; Kim KS; Ramakrishna S
Biochem Biophys Res Commun; 2019 Apr; 512(1):60-65. PubMed ID: 30862357
[TBL] [Abstract][Full Text] [Related]
20. Cyclin-Dependent Kinase-9 Is a Therapeutic Target in MYC-Expressing Diffuse Large B-Cell Lymphoma.
Hashiguchi T; Bruss N; Best S; Lam V; Danilova O; Paiva CJ; Wolf J; Gilbert EW; Okada CY; Kaur P; Drew L; Cidado J; Hurlin P; Danilov AV
Mol Cancer Ther; 2019 Sep; 18(9):1520-1532. PubMed ID: 31243099
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
